Please login to the form below

Not currently logged in
Email:
Password:

Daichii Sankyo

This page shows the latest Daichii Sankyo news and features for those working in and with pharma, biotech and healthcare.

Astellas, Daiichi Sankyo and Takeda to study biomarkers

Astellas, Daiichi Sankyo and Takeda to study biomarkers

Astellas, Daiichi Sankyo and Takeda to study biomarkers. Collaboration aims to establish comprehensive database to accelerate drug development. ... Japanese pharmaceutical firms Astellas, Daiichi Sankyo and Takeda have joined forces to create a

Latest news

  • AZ and Daiichi Sankyo sign Movantik marketing deal AZ and Daiichi Sankyo sign Movantik marketing deal

    AZ and Daiichi Sankyo sign Movantik marketing deal. Two firms have agreed the deal for the new constipation pill. ... AstraZeneca has announced a new co-commercialisation agreement with Daiichi Sankyo for the constipation drug Movantik (naloxegol) in the

  • Thin on the ground

    Daichii Sankyo is developing edoxaban tosylate, which is also an orally active direct factor Xa inhibitor.

  • News in brief, June 20, 2007

    Its clients include US and EU pharmaceutical and biotechnology corporations including Allergan, Biogen Idec, Bristol-Myers Squibb, sanofi-aventis and Daichii Sankyo.

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics